SQI Diagnostics Inc SQIDF

Primary Symbol: V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > RaliDx for Pneumonia

<< Previous

Bullboard Posts

Next >>

Comment by FactFinder1994on Sep 28, 2022 9:04am

71 Views

Post# 34991671

RE:RE:RaliDx for Pneumonia

Here are a few paragraphs from recent paper on RALI-Dx

Take Home Message: The RALI-Dx assay is a biomarker-based approach to emergency department triage for patients with respiratory illness and is superior to conventional strategies. This diagnostic test will help to optimize the utilization of scarce healthcare resources.

Conclusions: The rapid diagnostic biomarker panel accurately identified the need for inpatient care in patients presenting with respiratory symptoms, including COVID-19. The RALI-Dx test is broadly and easily applicable across many jurisdictions and represents an important diagnostic adjunct to advance emergency department decision- making protocols.

Introduction

Symptoms of respiratory tract infection are a common cause of emergency department (ED) visits. From 2018-2019 in Canada, more than 200,000 ED visits were associated with respiratory illness.1 This demand is traditionally increased in the seasonal flu months and has been further complicated in the COVID-19 pandemic,1 where ED visits for respiratory illness have dramatically increased to the point of repeatedly overwhelming health care systems worldwide.

In conclusion, a predictive model using a rapid inflammation diagnostic immunoassay (RALI-Dx) represents a valuable tool to accurately assess the individual patient’s host inflammatory response in patients presenting to an ED with respiratory illness. This pragmatic assay will augment the precision of clinical decision-making: to admit patients who are likely to develop severe illness, and safely discharge those on a milder course to recover outside of the hospital, thereby better managing limited health care resources. RALI-Dx measures the host inflammatory response in patients with any respiratory illness and, therefore, will be broadly applicable for patients with COVID-19, its variants, as well as any future respiratory pandemic.

Funding Sources: This study was funded in part by the Canadian Institutes of Health Research (FRN #440205) and SQI Diagnostics. Neither funder played any role in study design, data collection, analysis, interpretation of the data, writing the report, or in the decision to submit the paper for publication. All authors confirm access to all data collected throughout the study term.